Identification of sphingosine 1-phosphate level and MAPK/ERK signaling in pancreatic β cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Sphingosine kinase is a lipid kinase that phosphorylates sphingosine to generate sphingosine 1-phosphate (S1P). S1P regulates pancreatic islet β-cell endoplasmic reticulum stress and proliferation. Type 1 and type 2 diabetes share some key pathogenic processes. In this study, we investigated whether secretion of insulin and production of S1P is altered in alloxan and glucose-treated cells from the rat pancreatic β-cell line RIN-5F.Methods: RIN-5F cells were treated with 2 mM alloxan and 20 mM glucose for 6 hours or 24 hours before being evaluated by enzyme linked immunosorbent assay (ELISA) and Western blotting.Results: Insulin secretion and expression was higher in RIN-5F cells treated with glucose compared to control cells. In contrast, alloxan treatment did not affect insulin secretion and expression in RIN-5F cells. Interestingly, compared with normal control levels, S1P/EDG-5 was increased in both alloxan and glucose-treated pancreatic β cell than normal control. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) inhibition strongly decreased the expression of insulin and S1P in glucose- or alloxan-treated RIN-5F cells.Conclusion: We observe that production of S1P is increased in both diabetic cell models. In addition, MAPK/ERK signaling regulates secretion of insulin and S1P expression in pancreatic β-cells. Based on the literature and our findings, S1P may be a promising agent for the treatment of insulin-related disorders.
Abstract
Purpose: Sphingosine kinase is a lipid kinase that phosphorylates sphingosine to generate sphingosine 1-phosphate (S1P). S1P regulates pancreatic islet β-cell endoplasmic reticulum stress and proliferation. Type 1 and type 2 diabetes share some key pathogenic processes. In this study, we investigated whether secretion of insulin and production of S1P is altered in alloxan and glucose-treated cells from the rat pancreatic β-cell line RIN-5F.Methods: RIN-5F cells were treated with 2 mM alloxan and 20 mM glucose for 6 hours or 24 hours before being evaluated by enzyme linked immunosorbent assay (ELISA) and Western blotting.Results: Insulin secretion and expression was higher in RIN-5F cells treated with glucose compared to control cells. In contrast, alloxan treatment did not affect insulin secretion and expression in RIN-5F cells. Interestingly, compared with normal control levels, S1P/EDG-5 was increased in both alloxan and glucose-treated pancreatic β cell than normal control. Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) inhibition strongly decreased the expression of insulin and S1P in glucose- or alloxan-treated RIN-5F cells.Conclusion: We observe that production of S1P is increased in both diabetic cell models. In addition, MAPK/ERK signaling regulates secretion of insulin and S1P expression in pancreatic β-cells. Based on the literature and our findings, S1P may be a promising agent for the treatment of insulin-related disorders.
참고문헌 (26)
- Craig ME, "ISPAD Clinical Practice Consensus Guidelines 2014. Definition, epidemiology, and classification of diabetes in children and adolescents", Pediatr Diabetes, 15(Suppl 20), pp.4~17 (2014)
- White MF, "Insulin signaling in health and disease", Science, 302, pp.1710~1711 (2003)
- Pinhas-Hamiel O, "Acute and chronic complications of type 2 diabetes mellitus in children and adolescents", Lancet, 369, pp.1823~1831 (2007)
- Craig ME, "Diabetes care, glycemic control, and complications in children with type 1 diabetes from Asia and the Western Pacific Region", J Diabetes Complications, 21, pp.280~287 (2007)
- Saini V, "Molecular mechanisms of insulin resistance in type 2 diabetes mellitus", World J Diabetes, 1, pp.68~75 (2010)
- Arish M, "Implication of sphingosine-1-phosphate signaling in diseases : molecular mechanism and therapeutic strategies", J Recept Signal Transduct Res, 37, pp.437~446 (2017)
- Chen W, "Sphingosine 1-phosphate in metabolic syndrome(review)", Int J Mol Med, 38, pp.1030~1038 (2016)
- Rosen H, "Sphingosine-1-phosphate and its receptors : structure, signaling, and influence", Annu Rev Biochem, 82, pp.637~662 (2013)
- Ng ML, "The role of sphingolipid signalling in diabetes associated pathologies(review)", Int J Mol Med, 39, pp.243~252 (2017)
- Randriamboavonjy V, "The S1P(2)receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes", Basic Res Cardiol, 104, pp.333~340 (2009)
- Imasawa T, "Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells", Biochem Biophys Res Commun, 392, pp.207~211 (2010)
- Ali A. Al-Shatwi, "Aloe-Emodin Protects RIN-5F (Pancreatic β-cell) Cell from Glucotoxicity via Regulation of Pro-Inflammatory Cytokine and Downregulation of Bax and Caspase 3", Biomolecules & Therapeutics, 24(1), pp.49~56 (2016), 한국응용약물학회
- Spiegel S, "Sphingosine-1-phosphate : signaling inside and out", FEBS Lett, 476, pp.55~57 (2000)
- He Y, "Sphingosine-1-phosphate induces islet β-cell proliferation and decreases cell apoptosis in high-fat diet", streptozotocin diabetic mice, 2019, pp.18, 3415~3424
- Hatoum D, "Mammalian sphingosine kinase(SphK)isoenzymes and isoform expression : challenges for SphK as an oncotarget", Oncotarget, 8, pp.36898~36929 (2017)
- Haass NK, "Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage", Biomed Res Int, 2015, pp.165105~ (2015)
- Ighodaro OM, "Alloxaninduced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies", Medicina(Kaunas), 53, pp.365~374 (2017)
- Wysham C, "Beta-cell failure in type 2 diabetes : mechanisms, markers, and clinical implications", Postgrad Med, 132, pp.676~686 (2020)
- Poitout V, "Minireview : secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity", Endocrinology, 143, pp.339~342 (2002)
- Tsubouchi H, "Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement", Free Radic Biol Med, 39, pp.444~452 (2005)
- Rho HW, "Protective mechanism of glucose against alloxan-induced beta-cell damage : pivotal role of ATP", Exp Mol Med, 32, pp.12~17 (2000)
- Lei H, "Effects of sesamin on streptozotocin(STZ)-induced NIT-1 pancreatic β-cell damage", Int J Mol Sci, 13, pp.16961~16970 (2012)
- Longuet C, "Extracellularly regulated kinases 1", 2(p44, Endocrinology, pp.2005, 146[DOI]
- Holland WL, "Sphingolipids, insulin resistance, and metabolic disease : new insights from in vivo manipulation of sphingolipid metabolism", Endocr Rev, 29, pp.381~402 (2008)
- Maceyka M, "Sphingosine-1-phosphate signaling and its role in disease", Trends Cell Biol, 22, pp.50~60 (2012)
- Holm LJ, "Abnormal islet sphingolipid metabolism in type 1 diabetes", Diabetologia, 61, pp.1650~1661 (2018)